Humanitas Mirasole S.p.A.

At Humanitas Mirasole S.p.A. in Milan, clinical trials in nervous system diseases focus on traumatic brain injury and recovery after serious neurological damage. These studies are designed to assess whether new approaches can improve safety, tolerability, and clinical outcomes for critically injured patients.

• Subacute traumatic brain injury
• Moderate to severe brain injury recovery
• Testing an intranasal therapy for neurological support

This research aims to expand treatment options for patients with acute brain injury while improving how neurological recovery is supported in the hospital setting.

A major part of the site’s work centers on neoplasms, especially ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Many trials are evaluating new therapies and maintenance strategies to improve disease control, delay progression, and extend survival in recurrent or platinum-resistant disease.

• Advanced and recurrent ovarian cancer
• Platinum-resistant ovarian cancer
• Maintenance treatment after initial therapy
• Testing targeted and antibody-based treatments

The research portfolio includes studies in biomarker-selected populations, reflecting a strong interest in more personalized treatment for women with difficult-to-treat gynecologic cancers.

Another prominent area at Humanitas Mirasole S.p.A. is female urogenital diseases, with trials in endometrial cancer, cervical cancer, and vulvar cancer. These studies are exploring new treatment combinations, maintenance options, and better ways to identify patients most likely to benefit from targeted therapy.

• Advanced or recurrent endometrial cancer
• Locally advanced and metastatic cervical cancer
• Vulvar cancer and HPV-related lesions
• Evaluating treatment effectiveness and disease response

The site is actively involved in research that combines precision medicine with clinical outcome assessment, aiming to improve care across multiple gynecologic malignancies.

Several trials at this Milan site address a broad range of solid tumors, including head and neck cancer, pancreatic cancer, colorectal cancer, and lung cancer. The main goal is to test new targeted therapies and immunotherapy-based strategies for patients with advanced or relapsed disease.

• Advanced solid tumors with specific molecular features
• Head and neck squamous cell carcinoma
• Pancreatic and colorectal cancers
• Assessing tumor response and survival outcomes

This research reflects a strong precision-oncology focus, with studies designed to match therapies to tumor biology and improve outcomes in hard-to-treat cancers.

The site also contributes to bacterial infections and mycoses research, alongside studies in pathological conditions, signs and symptoms seen in critically ill patients. These trials often aim to improve survival, optimize supportive care, or refine treatment approaches in intensive care and other high-risk settings.

• Critically ill patients requiring mechanical ventilation
• Improving survival in intensive care
• Supportive care and treatment optimization
• Broad clinical research across complex disease settings

Together, these studies show a diverse research program that extends beyond oncology into infection-related care and critical illness management.